Re-irradiation with interstitial brachytherapy in uterine cancer patients with vaginal recurrence after post-operative pelvic irradiation.
high-dose-rate brachytherapy
image-guided adaptive brachytherapy
interstitial brachytherapy
post-operative radiotherapy
vaginal recurrence
Journal
Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
05
04
2021
accepted:
28
11
2021
entrez:
2
3
2022
pubmed:
3
3
2022
medline:
3
3
2022
Statut:
ppublish
Résumé
This study aimed to evaluate the outcomes and dose-volume parameters of re-irradiation with interstitial brachytherapy (ISBT) in uterine cancer patients with vaginal recurrence after post-operative pelvic irradiation. We evaluated six uterine cancer patients who received re-irradiation with ISBT between January, 2012 and December, 2016. As an initial treatment, all patients received post-operative whole pelvic irradiation of 45-50.4 Gy in 25-28 fractions. For vaginal recurrence, all patients were treated with ISBT alone at a dose of 38-42 Gy in 6-7 fractions for clinical target volumes (CTVs) for 3-4 days. Post-operative pelvic irradiation was delivered to five and one patients, using a three-dimensional conformal technique and intensity-modulated radiotherapy, respectively. Median duration from surgery to vaginal recurrence was 25.7 months. Median tumor size just before ISBT was 3.3 cm. Median time from completion of pelvic irradiation to ISBT initiation was 24.1 months. Mean doses per fraction of ISBT for CTV D Re-irradiation with ISBT may be an effective treatment strategy for gynecological cancer patients with vaginal recurrence after post-operative pelvic irradiation.
Identifiants
pubmed: 35233236
doi: 10.5114/jcb.2022.113550
pii: 46413
pmc: PMC8867233
doi:
Types de publication
Journal Article
Langues
eng
Pagination
60-65Informations de copyright
Copyright © 2022 Termedia.
Déclaration de conflit d'intérêts
The authors report no conflict of interest.
Références
Gynecol Oncol. 2006 Dec;103(3):1023-30
pubmed: 16890276
Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):1013-20
pubmed: 11429229
Brachytherapy. 2014 May-Jun;13(3):219-24
pubmed: 24559794
Int J Gynecol Cancer. 2014 Jan;24(1):141-8
pubmed: 24362719
Br J Radiol. 1985 Jun;58(690):515-28
pubmed: 4063711
J Clin Oncol. 2000 Apr;18(8):1606-13
pubmed: 10764420
Gynecol Oncol. 2005 Mar;96(3):721-8
pubmed: 15721417
Gynecol Oncol. 1998 May;69(2):125-9
pubmed: 9600819
Med Oncol. 2006;23(2):219-23
pubmed: 16720922
Obstet Gynecol. 1989 Jun;73(6):1027-34
pubmed: 2726106
J Natl Compr Canc Netw. 2019 Jan;17(1):64-84
pubmed: 30659131
Radiother Oncol. 2016 Sep;120(3):412-419
pubmed: 27396811
Clin Oncol (R Coll Radiol). 2020 Jan;32(1):43-51
pubmed: 31402286
Brachytherapy. 2014 Nov-Dec;13(6):554-61
pubmed: 25056640
J Natl Compr Canc Netw. 2018 Feb;16(2):170-199
pubmed: 29439178
Gynecol Oncol. 2013 Dec;131(3):586-92
pubmed: 24029418
J Contemp Brachytherapy. 2016 Oct;8(5):415-421
pubmed: 27895683
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Radiother Oncol. 2014 Oct;113(1):126-31
pubmed: 25241996
Br J Cancer. 2009 Oct 6;101(7):1059-65
pubmed: 19738606
Int J Radiat Oncol Biol Phys. 1985 Jan;11(1):87-96
pubmed: 3881377
Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):169-76
pubmed: 16427212
Int J Gynecol Cancer. 2014 Jun;24(5):916-22
pubmed: 24442006
Brachytherapy. 2012 Jan-Feb;11(1):68-75
pubmed: 22265440
Oncology. 2007;72(1-2):33-8
pubmed: 17998788
Int J Gynecol Cancer. 2009 May;19(4):777-81
pubmed: 19509587